JP2005509663A5 - - Google Patents

Download PDF

Info

Publication number
JP2005509663A5
JP2005509663A5 JP2003545313A JP2003545313A JP2005509663A5 JP 2005509663 A5 JP2005509663 A5 JP 2005509663A5 JP 2003545313 A JP2003545313 A JP 2003545313A JP 2003545313 A JP2003545313 A JP 2003545313A JP 2005509663 A5 JP2005509663 A5 JP 2005509663A5
Authority
JP
Japan
Prior art keywords
formula
day
days
administered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003545313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005509663A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/012572 external-priority patent/WO2003043632A2/en
Publication of JP2005509663A publication Critical patent/JP2005509663A/ja
Publication of JP2005509663A5 publication Critical patent/JP2005509663A5/ja
Pending legal-status Critical Current

Links

JP2003545313A 2001-11-20 2002-11-11 癌治療のための方法 Pending JP2005509663A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33397701P 2001-11-20 2001-11-20
US60/333,977 2001-11-20
PCT/EP2002/012572 WO2003043632A2 (en) 2001-11-20 2002-11-11 Use of bisindolmaleimide and gemcitabine for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2005509663A JP2005509663A (ja) 2005-04-14
JP2005509663A5 true JP2005509663A5 (enExample) 2005-12-22

Family

ID=23305029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545313A Pending JP2005509663A (ja) 2001-11-20 2002-11-11 癌治療のための方法

Country Status (8)

Country Link
US (1) US20030139373A1 (enExample)
EP (1) EP1448189A2 (enExample)
JP (1) JP2005509663A (enExample)
CN (1) CN1589143A (enExample)
AR (1) AR037543A1 (enExample)
AU (1) AU2002366195A1 (enExample)
CA (1) CA2465807A1 (enExample)
WO (1) WO2003043632A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
WO2018092020A1 (en) 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
PE91698A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
HRP20000585B1 (en) * 1998-03-17 2009-02-28 F. Hoffmann - La Roche Ag Substituted bisindolymaleimides for the inhibition of cell proliferation
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6281356B1 (en) * 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
AU2001271257A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6548531B2 (en) * 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy

Similar Documents

Publication Publication Date Title
RU2010133489A (ru) Применение ингибиторов гамма-секретазы для лечения рака
JP2009102342A5 (enExample)
RU98104448A (ru) Оральные быстрорастворяющиеся композиции агонистов допамина
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
JP2005537268A5 (enExample)
JP2017525718A5 (enExample)
JP2010526089A5 (enExample)
JP2004517843A5 (enExample)
RU2009101324A (ru) Композиции и способы лечения воспаления слизистой оболочки
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
JP2007502832A5 (enExample)
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
JP2009517411A5 (enExample)
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
SG175895A1 (en) Antitumor combination including ave8062 and sorafenib
CA2435921A1 (en) Method of cancer therapy
RU2004133387A (ru) Фармацевтический препарат с немедленным высвобождением
JP2005509663A5 (enExample)
JP2019513812A5 (enExample)
JP2002509154A5 (enExample)
CN1615136A (zh) 包含埃坡霉素和抗代谢物的组合
RU2017137008A (ru) Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени
EA200600377A1 (ru) Новая композиция
CN1010550B (zh) 制备改进的抗炎药剂的方法
JP2001508769A (ja) アレンドロン酸塩及び胃排出を促進する薬剤を含有する医薬組成物